Literature DB >> 21762832

Screening for depression in patients with hepatitis C using the Beck Depression Inventory-II: do somatic symptoms compromise validity?

Alexander L Patterson1, Benjamin J Morasco, Bret E Fuller, David W Indest, Jennifer M Loftis, Peter Hauser.   

Abstract

OBJECTIVE: The objective of the study was to evaluate the validity of the Beck Depression Inventory-II (BDI-II) when used to measure depression in patients with hepatitis C virus (HCV).
METHOD: Factor analysis was utilized to validate the BDI-II in a sample of 671 patients with HCV recruited from a large Veterans Affairs medical center. The data were split randomly: the first half was subjected to exploratory factor analysis, and confirmatory factor analysis was used with the second half to confirm the model. Diagnostic data were retrieved from the electronic medical records.
RESULTS: Subjects were 97.0% male, average age was 52.8 years, 16.1% had a cirrhosis diagnosis, 62.9% had a current major depressive disorder diagnosis, and 42.3% endorsed significant depressive symptoms on the BDI-II. A two-factor model was an excellent fit for the data; the factors were labeled Cognitive-Affective and Somatic. Patients scored significantly higher on the Somatic factor than on the Cognitive-Affective factor (P<.001), and this discrepancy increased when comparing patients based on whether they had a diagnosis of cirrhosis.
CONCLUSIONS: When screening for depression in HCV patients, questions targeting cognitive and affective symptoms of depression may provide a more valid measurement of depression than questions targeting somatic symptoms of depression, particularly for patients with more advanced liver disease. Published by Elsevier Inc.

Entities:  

Mesh:

Year:  2011        PMID: 21762832     DOI: 10.1016/j.genhosppsych.2011.04.005

Source DB:  PubMed          Journal:  Gen Hosp Psychiatry        ISSN: 0163-8343            Impact factor:   3.238


  18 in total

1.  Efficacy and tolerability of interferon-free regimen for patients with genotype-1 HCV infection.

Authors:  Kosuke Takeda; Ryuichi Noguchi; Tadashi Namisaki; Kei Moriya; Takemi Akahane; Mitsuteru Kitade; Hideto Kawaratani; Naotaka Shimozato; Kosuke Kaji; Hiroaki Takaya; Yasuhiko Sawada; Kenichiro Seki; Yukihisa Fujinaga; Yuki Tsuji; Takuya Kubo; Shinya Sato; Soichiro Saikawa; Keisuke Nakanishi; Masanori Furukawa; Koh Kitagawa; Takahiro Ozutsumi; Daisuke Kaya; Akira Mitoro; Tsuyoshi Mashitani; Yasushi Okura; Junichi Yamao; Hitoshi Yoshiji
Journal:  Exp Ther Med       Date:  2018-07-19       Impact factor: 2.447

2.  Multimethod assessment of baseline depression and relationship to hepatitis C treatment discontinuation.

Authors:  Jeffrey J Weiss; Sarah Prieto; Norbert Bräu; Douglas T Dieterich; Sue M Marcus; Alicia Stivala; Jack M Gorman
Journal:  Int J Psychiatry Med       Date:  2018-01-03       Impact factor: 1.210

3.  Vulnerability to somatic symptoms of depression during interferon-alpha therapy for hepatitis C: a 16-week prospective study.

Authors:  Jennifer M Loftis; Alexander L Patterson; Clare J Wilhelm; Henry McNett; Benjamin J Morasco; Marilyn Huckans; Timothy Morgan; Shira Saperstein; Aliya Asghar; Peter Hauser
Journal:  J Psychosom Res       Date:  2012-11-21       Impact factor: 3.006

Review 4.  Assessment of mental health in patients with chronic liver disease.

Authors:  Maureen P Whitsett; Arpita Goswami Banerjee; Marina Serper
Journal:  Clin Liver Dis (Hoboken)       Date:  2022-07-16

5.  Factor structure and clinical utility of BDI-II factor scores in postpartum women.

Authors:  Nanmathi Manian; Elizabeth Schmidt; Marc H Bornstein; Pedro Martinez
Journal:  J Affect Disord       Date:  2013-03-19       Impact factor: 4.839

6.  Adipocytokine signaling is altered in Flinders sensitive line rats, and adiponectin correlates in humans with some symptoms of depression.

Authors:  Clare J Wilhelm; Dongseok Choi; Marilyn Huckans; Laura Manthe; Jennifer M Loftis
Journal:  Pharmacol Biochem Behav       Date:  2012-11-12       Impact factor: 3.533

7.  A longitudinal study evaluating the effects of interferon-alpha therapy on cognitive and psychiatric function in adults with chronic hepatitis C.

Authors:  Marilyn Huckans; Bret Fuller; Viva Wheaton; Sarah Jaehnert; Carilyn Ellis; Michael Kolessar; Daniel Kriz; Jeanne Renee Anderson; Kristin Berggren; Hannah Olavarria; Anna W Sasaki; Michael Chang; Kenneth D Flora; Jennifer M Loftis
Journal:  J Psychosom Res       Date:  2014-08-07       Impact factor: 3.006

8.  Pain-related anxiety mediates the relationship between depressive symptoms and pain interference in veterans with hepatitis C.

Authors:  Melissa H Adams; Travis I Lovejoy; Dennis C Turk; Steven K Dobscha; Peter Hauser; Benjamin J Morasco
Journal:  Gen Hosp Psychiatry       Date:  2015-07-17       Impact factor: 3.238

Review 9.  Psychiatric and substance use disorders co-morbidities and hepatitis C: Diagnostic and treatment implications.

Authors:  Peter Hauser; Shira Kern
Journal:  World J Hepatol       Date:  2015-07-28

10.  Evaluation of depression, anxiety and quality of life in hepatitis C patients who treated with direct acting antiviral agents.

Authors:  Oğuzhan Kesen; Haluk Tarık Kani; Ömer Yanartaş; Umut Emre Aykut; Bedin Gök; Feyza Gündüz; Yusuf Yılmaz; Osman Cavit Özdoğan; Yeşim Özen Alahdab
Journal:  Turk J Gastroenterol       Date:  2019-09       Impact factor: 1.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.